Uniqure N.v (QURE) Stock
Gene therapy company targeting rare genetic disorders. Here's the price, business snapshot, and what's worth knowing about Uniqure N.v in October 2026.
uniQure NV (QURE) is a biotechnology company focused on developing and commercialising gene therapies using viral vector platforms, particularly adeno‑associated viruses (AAVs). The firm targets rare genetic disorders — including haemophilia and select neurological conditions — with the aim of delivering durable, potentially one‑time treatments rather than chronic medication. Its market capitalisation is approximately $3.89 billion, reflecting investor expectations around clinical progress and regulatory decisions. Key investor considerations include clinical trial outcomes, regulatory approvals, the complexity and cost of scaling viral‑vector manufacturing, and competition in the gene‑therapy space. Revenue today is limited and may depend on future product approvals, partnerships or licensing deals. Shares tend to be sensitive to trial readouts, filings and collaboration announcements, making them relatively volatile. This information is for educational purposes only and not personal financial advice; values can rise or fall and past performance is not a reliable guide to future results.
Uniqure N.v (QURE) Stock Forecast
Analyst price target, next 12 months
$49.00
+108.9% vs today's $23.46
Price range over the last 12 months
In the middle of its 12-month range
Analysts covering Uniqure N.v have a consensus 12-month target of $49.00, above the current price of $23.46.
Analyst targets are opinions, not guarantees. Capital at risk. Data as of 5 Oct 2026.
Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying UNIQURE's stock, believing it could rise significantly in value.
Financial Health
UNIQURE N.V. shows strong revenue and cash flow, indicating good financial stability and growth potential.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Gene‑therapy focus
uniQure's core expertise is in AAV‑based gene therapy, which promises durable effects; however, clinical and manufacturing hurdles mean outcomes can vary.
Rare disease market
Targeting haemophilia and other rare conditions offers high unmet need and potential value, yet commercial uptake depends on pricing, reimbursement and long‑term data.
Regulatory milestones
Trial readouts and approval decisions drive valuation swings; these catalysts can create opportunities but also pose binary risks for investors.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
